Page 8 - Demo

Journal of Rural Medicine%u4e61%u6751%u533b%u5b66%u7b2c 2 %u5377%u25c6%u7b2c 4 %u671f%u25c6%u7248%u672c 1.0 %u25c6 2025 %u5e74%u6587%u7ae0%u7c7b%u578b%uff1a%u8bba%u6587 | %u520a%u53f7%uff08ISSN%uff09%uff1a3060-947X2 Copyright %u00a9 This work is licensed under a Commons Attibution-Non Commercial 4.0 International License.schizophrenia who received treatment with amisulpride tablets. Using single factor analysis and multiple linear regression to analyze the influencing factors of blood concentration of amisulpride; Evaluate the effectiveness of patients receiving amisulpride treatment based on the PANSS scoring results and reduction rate.Result%uff1aA total of 142 patients were included, with a median blood concentration of amisulpride and a plasma concentration/dose ratio (C/D) of 458.7ng/mL and 8.38, respectively. The body mass index (BMI) is significantly negatively correlated with the C/D value of amisulpride (p<0.05). Patients were grouped according to BMI, and among obese patients (BMI %u2265 28kg/m2), the C/D value of middle-aged and elderly patients was significantly higher than that of young patients (p<0.05); In overweight patients (24kg/m2 %u2264 BMI<28kg/m2), the C/D value of female young patients is significantly higher than that of male young patients (p<0.05). ROC analysis showed that the blood concentration of amisulpride was 487.8ng/mL when the score reduction rate reached 50%. The correlation analysis between the blood concentration of amisulpride and adverse reactions in patients showed that there were no cases of renal dysfunction in the patient population with blood concentration higher than 487.8ng/mL, and there was no significant correlation between drug concentration and prolactin levels, abnormal electrocardiogram, liver function and other adverse reactions (p>0.05).Conclusion: In this study, the blood concentration of amisulpride in patients was generally higher than the recommended drug monitoring concentration range in the guidelines, and BMI was an important influencing factor on their C/D values. When the treatment efficacy reached 50%, the blood concentration of amisulpride was 487.8ng/mL and showed good safety, providing an important reference for developing a monitoring range of amisulpride blood concentration suitable for Chinese patients with schizophrenia.%u3010Key words%u3011Amisulpride%uff1bPlasma concentration%uff1bBMI%uff1bTreatment reference range%u5f15%u8a00%u7cbe%u795e%u5206%u88c2%u75c7%u662f%u4e00%u79cd%u6162%u6027%u4e25%u91cd%u7684%u7cbe%u795e%u75be%u75c5%uff0c%u8fd1%u5e74%u6765%u88ab%u5217%u4e3a%u5168%u7403%u6b8b%u75be%u7684%u4e3b%u8981%u539f%u56e0%u4e4b%u4e00 [1-3]%u3002%u6c28%u78fa%u5fc5%u5229%u662f%u975e%u5178%u578b%u6297%u7cbe%u795e%u75c5%u836f%u7684%u4ee3%u8868%u6027%u836f%u7269%uff0c%u5bf9 D2/D3 %u53d7%u4f53%u5177%u6709%u53cc%u6548%u8c03%u8282%u7279%u6027%uff0c%u5c0f%u5242%u91cf%u65f6%u901a%u8fc7%u6291%u5236%u7a81%u89e6%u524d%u53d7%u4f53%u589e%u52a0%u591a%u5df4%u80fa%u4f20%u9012%u6539%u5584%u9634%u6027%u75c7%u72b6%uff0c%u5927%u5242%u91cf%u65f6%u5219%u901a%u8fc7%u963b%u65ad%u7a81%u89e6%u540e%u53d7%u4f53%u8c03%u63a7%u9633%u6027%u75c7%u72b6 [4-6]%uff0c%u56e0%u800c%u5bf9%u9633%u6027%u6216%u9634%u6027%u75c7%u72b6%u4e3a%u4e3b%u7684%u7cbe%u795e%u5206%u88c2%u75c7%u60a3%u8005%u5177%u6709%u826f%u597d%u7684%u7597%u6548%u3002%u56e0%u5176%u5bf9D3 %u53d7%u4f53%u9009%u62e9%u6027%u9ad8%u4e8e%u5178%u578b%u6297%u7cbe%u795e%u75c5%u836f%u7269%uff0c%u800c%u5bf9%u4e8e%u5176%u4ed6%u975e%u591a%u5df4%u80fa%u53d7%u4f53%uff085-HT%u3001M%u3001H1 %u7b49%uff09%u7684%u4eb2%u548c%u529b%u8f83%u4f4e%uff0c%u6240%u4ee5%u5728%u6539%u5584%u75be%u75c5%u7684%u540c%u65f6%uff0c%u9525%u4f53%u5916%u7cfb%u526f%u53cd%u5e94%u7684%u53d1%u751f%u7387%u66f4%u4f4e%uff0c%u4e5f%u4e0d%u6613%u5f15%u8d77%u4f53%u91cd%u589e%u52a0%u3001%u55dc%u7761%u3001%u4fbf%u79d8%u7b49%u4e0d%u826f%u53cd%u5e94 [7-9]%uff0c%u4f46%u6613%u9020%u6210%u50ac%u4e73%u7d20%u5347%u9ad8%u3001QTc %u95f4%u671f%u5ef6%u957f%u7b49%u98ce%u9669%u3002%u4f5c%u4e3a%u4e34%u5e8a%u4e00%u7ebf%u6cbb%u7597%u836f%u7269%uff0c%u6c28%u78fa%u5fc5%u5229%u7684%u8840%u836f%u6d53%u5ea6%u4e0e%u7597%u6548%u548c%u4e0d%u826f%u53cd%u5e94 ( %u5fc3%u810f%u6bd2%u6027%u3001%u9ad8%u50ac%u4e73%u7d20%u8840%u75c7%u7b49 )%u5bc6%u5207%u76f8%u5173 [10-11]%u30022017 %u5e74%u56fd%u9645%u795e%u7ecf%u7cbe%u795e%u836f%u7406%u5b66%u4e0e%u836f%u7269%u7cbe%u795e%u75c5%u5b66%u534f%u4f1a%uff08AGNP%uff09%u5efa%u8bae [12] %u5c06%u6cbb%u7597%u836f%u7269%u76d1%u6d4b%uff08TDM%uff09%u4f5c%u4e3a%u6c28%u78fa%u5fc5%u5229%u4e34%u5e8a%u5e94%u7528%u7684%u5e38%u89c4%u76d1%u6d4b%u624b%u6bb5%uff0c%u5e76%u5efa%u8bae%u5176%u8840%u836f%u6d53%u5ea6%u76d1%u6d4b%u8303%u56f4%u4e3a 100 %uff5e 320ng/mL%u3002%u7136%u800c%uff0c%u4e2a%u4f53%u4e4b%u95f4%u7684%u836f%u7269%u6e05%u9664%u7387%u548c%u836f%u4ee3%u52a8%u529b%u5b66%u5b58%u5728%u663e%u8457%u5dee%u5f02 [13-14]%uff0c%u56e0%u6b64%u4e0d%u540c%u60a3%u8005%u4e4b%u95f4%u8840%u836f%u6d53%u5ea6%u5b58%u5728%u8f83%u5927%u7684%u4e2a%u4f53%u5dee%u5f02 [15]%uff0c%u5176%u4e2d%uff0c%u60a3%u8005%u7684%u5e74%u9f84%u3001%u6027%u522b%u3001%u7ed9%u836f%u5242%u91cf%u3001BMI%u3001%u5408%u5e76%u7528%u836f%u3001%u5438%u70df%u4e60%u60ef%u4ee5%u53ca%u9057%u4f20%u53d8%u5f02%u5747%u662f%u5f15%u8d77%u60a3%u8005%u836f%u7269%u4ee3%u8c22%u4ea7%u751f%u5dee%u5f02%u7684%u6f5c%u5728%u56e0%u7d20%uff0c%u8fd9%u53ef%u80fd%u662f%u4e0d%u540c%u60a3%u8005%u7fa4%u4f53%u7684%u7814%u7a76%u7ed3%u679c%u5b58%u5728%u5f02%u8d28%u6027%u7684%u91cd%u8981%u539f%u56e0%u3002%u4f8b%u5982%uff0cM%u00fcller%u3001J%u00f6nsson %u7b49%u4eba%u7684%u7814%u7a76%u8868%u660e%u5973%u6027%u6c28%u78fa%u5fc5%u5229 C/D%u663e%u8457%u9ad8%u4e8e%u7537%u6027 [16-18]%uff0c%u800c%u738b%u6bc5%u5947%u3001%u738b%u5360%u748b%u7b49%u4eba%u7684%u7814%u7a76%u4e2d [19-22] %u63d0%u793a%u6027%u522b%u5f15%u8d77%u7684%u6c28%u78fa%u5fc5%u5229 C/D %u503c%u7684%u5dee%u5f02%u65e0%u7edf